Radius Health, a US-based developer of drug therapies for osteoporosis and women’s health backed by Switzerland-based peer Novartis, has raised $43m after pulling its planned stock market flotation at the end of last year.

Novartis’s pharmaceutical business unit invested in Radius’ latest round through its joint programme with venture capital firm MPM Capital’s MPM Bio IV NVS Strategic Fund.

The other investors were MPM’s main venture fund and VC peers F2 Biosciences III, Biotech Growth, Brookside Capital and BB Biotech…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?